Nexalin Technology, Inc. (NXL)
Market Cap | 11.46M |
Revenue (ttm) | 158,860 |
Net Income (ttm) | -4.94M |
Shares Out | 7.59M |
EPS (ttm) | -0.66 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 932,817 |
Open | 1.640 |
Previous Close | 1.660 |
Day's Range | 1.440 - 1.720 |
52-Week Range | 0.253 - 4.050 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Aug 8, 2024 |
About NXL
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The compan... [Read more]
Financial Performance
In 2023, NXL's revenue was $110,748, a decrease of -91.62% compared to the previous year's $1.32 million. Losses were -$4.65 million, 173.8% more than in 2022.
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/a/d/press4-2505412.jpg)
Nexalin Technology Announces Closing of $5.2 Million Public Offering
HOUSTON, TX, July 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced the closing of its previously announced public offering of 3,0...
![](https://cdn.snapi.dev/images/v1/k/p/press4-2501204.jpg)
Nexalin Technology Announces Pricing of $5.2 Million Public Offering
HOUSTON, TX, June 27, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced the pricing of a public offering of 3,000,000 shares of common...
![](https://cdn.snapi.dev/images/v1/f/0/press6-2487873.jpg)
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer's and Dementia
HOUSTON, TEXAS, June 20, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced that the United States Patent and Trademark Office (USPTO) ...
![](https://cdn.snapi.dev/images/v1/d/t/press8-2480082.jpg)
Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / June 14, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) ("Nexalin") and VolitionRX Limited (NYSE American:VNRX) ("Volition") on the ...
![](https://cdn.snapi.dev/images/v1/6/s/press17-2478654.jpg)
Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
Brazil represents the 9th largest economy in the world with more than 35 million afflicted by mental health disorders Brazil represents the 9th largest economy in the world with more than 35 million a...
![](https://cdn.snapi.dev/images/v1/y/6/conf16-2461262.jpg)
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
HOUSTON, TX, June 04, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced today that it will be participating in the Spring MicroCap Rodeo Con...
![](https://cdn.snapi.dev/images/v1/d/g/press7-2458883.jpg)
FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024 Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024
![](https://cdn.snapi.dev/images/v1/q/f/press9-2443306.jpg)
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
HOUSTON, TX, May 22, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to announce its new division, Nexalin America, has been selected to ...
![](https://cdn.snapi.dev/images/v1/a/t/press19-2391601.jpg)
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
HOUSTON, TEXAS, April 25, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market (“...
![](https://cdn.snapi.dev/images/v1/2/3/press20-2365113.jpg)
Nexalin Technology CEO Provides Letter to Shareholders
Reports on growing clinical data supporting its neurostimulation technology and progress advancing its new Gen-3 HALO™ Clarity Virtual Clinic model Reports on growing clinical data supporting its neur...
![](https://cdn.snapi.dev/images/v1/p/n/press5-2357133.jpg)
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
New method of use patent covers key aspects of the technology that enable patients to receive treatment from the privacy of their own homes New method of use patent covers key aspects of the technolog...
![](https://cdn.snapi.dev/images/v1/w/u/press5-2351966.jpg)
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
Previously served as Acting General Counsel to the Department of Veterans Affairs Previously served as Acting General Counsel to the Department of Veterans Affairs
![](https://cdn.snapi.dev/images/v1/l/o/press5-2346093.jpg)
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
Collaborative Study involving the VA and UCSD achieved statistically significant decrease in PCS and PTSD symptoms versus control group
![](https://cdn.snapi.dev/images/v1/j/w/press8-2324194.jpg)
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin's Technology
Mental Health Center Initially Focused on Treatment of Patients with Substance Abuse Disorder Mental Health Center Initially Focused on Treatment of Patients with Substance Abuse Disorder
![](https://cdn.snapi.dev/images/v1/v/g/press5-2322095.jpg)
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
Event hosted by the U.S. Army Medical Research and Development Command's (USAMRDC) Combat Casualty Care Research Program (CCCRP) Neurotrauma Portfolio and the Biomedical Advanced Research and Developm...
![](https://cdn.snapi.dev/images/v1/z/c/press8-2310756.jpg)
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
Clinical study demonstrated clinically meaningful and statistically significant improvements in key sleep parameters, compared to adult patients treated with placebo Data published in Journal of Psych...
![](https://cdn.snapi.dev/images/v1/w/i/press10-2266907.jpg)
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
Company's International Reach Expanding with Latest Regulatory Approval Company's International Reach Expanding with Latest Regulatory Approval
![](https://cdn.snapi.dev/images/v1/e/f/press8-2240169.jpg)
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
HOUSTON, TX, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has...
![](https://cdn.snapi.dev/images/v1/r/y/press18-2225616.jpg)
Nexalin Technology Unveils Next-Generation HALO™ Clarity
A new neurostimulation device to combat the growing global mental health epidemic Designed for drug-free treatment of mental health conditions from the privacy of one's home with virtual monitoring by...
![](https://cdn.snapi.dev/images/v1/k/i/press4-2199975.jpg)
Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression
Results published in General Psychiatry, a leading peer-reviewed journal Results published in General Psychiatry, a leading peer-reviewed journal
![](https://cdn.snapi.dev/images/v1/w/b/press1-2119637.jpg)
Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter
HOUSTON, TEXAS, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the formation of a Military & Government Advisory Board ( ...
![](https://cdn.snapi.dev/images/v1/c/j/press18-2104461.jpg)
Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin's Neurostimulation Device to Penetrate Deep Brain Structures
Study reveals that Nexalin's non-invasive, deep frequency stimulation medical device can directly stimulate the deep intracranial nuclei, an area of the brain frequently associated with trauma and men...
![](https://cdn.snapi.dev/images/v1/z/o/press13-2009645.jpg)
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms
HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided an update on the growing body of clinical data supporting the poten...
![](https://cdn.snapi.dev/images/v1/l/m/press15-2004345.jpg)
Nexalin's CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time
HOUSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its Chief Executive Officer, Mark White, will be participatin...
![](https://cdn.snapi.dev/images/v1/h/j/press8-1988828.jpg)
Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies
HOUSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the formation of a new division, to be called “Nexalin America,” a...